REGISTRY PLATFORM INTO DIAGNOSIS, TREATMENT AND OUTCOME OF LUNG CANCER PATIENTS
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 6,000
- 试验地点
- 39
- 主要终点
- Frequency of molecular/mutational analysis
研究概览
简要总结
Observational, prospective clinical research, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Turkey
详细描述
In Turkey, non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in men and one of the most common causes of cancer-related deaths in women. Because of the heterogeneity of NSCLC or SCLC, it is crucial to characterize the biology of the tumor as exact as possible, to predict the course of disease as accurate as possible, and to determine the optimal therapeutic algorithm as early as possible after initial diagnostic work-up.
These efforts are an obligatory part of the initial diagnostics, since thorough knowledge of the biology of the disease and the resulting therapeutic options ensure optimal care of Volunteers with NSCLC or SCLC. The aim of REGISTURK is to set up a national clinical research platform to document molecular testing, treatment and course of disease of patients with NSCLC or SCLC.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient histopathologically diagnosed with non-small cell lung cancer or small cell lung cancer
- •Written informed consent no later than six weeks after start of first-line treatment
- •Age ≥ 18 years
排除标准
- •Volunteers participating in a research program for non-small cell or small cell lung cancer that includes interventions outside of routine clinical trial
结局指标
主要结局
Frequency of molecular/mutational analysis
时间窗: throughout of treatment, 36 months
To collect data on the frequency of molecular/mutational biomarker testing
Type of molecular/mutational analysis
时间窗: throughout of treatment, 36 months
To collect data on the type of molecular/mutational biomarker testing
次要结局
- The Rate of Response Rate(throughout of treatment, 36 months)
- Type of treatment(throughout of treatment, 36 months)
- The frequency of comorbidities(throughout of treatment, 36 months)
- Advers events rate(throughout of treatment, 36 months)
- Progression free survival time(throughout of treatment, 36 months)
- Overall survival time(throughout of treatment, 36 months)
研究者
Mahmut Gumus
Board Member of Oncological Clinical Research Association
Oncological Clinical Research Association, Turkey